Cargando…

Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience

SIMPLE SUMMARY: Hepatocellular cancer is the most common type of primary liver cancer. It is the third leading cause of cancer-related deaths worldwide and its incidence is increasing: >1 million new cases per year expected by 2025. Despite advances in treatment in recent years, diagnosis is asso...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sinner, Friedrich, Pinter, Matthias, Scheiner, Bernhard, Ettrich, Thomas Jens, Sturm, Niklas, Gonzalez-Carmona, Maria A., Waidmann, Oliver, Finkelmeier, Fabian, Himmelsbach, Vera, De Toni, Enrico N., Ben Khaled, Najib, Mohr, Raphael, Fründt, Thorben Wilhelm, Kütting, Fabian, van Bömmel, Florian, Lieb, Sabine, Krug, Sebastian, Bettinger, Dominik, Schultheiß, Michael, Jochheim, Leonie S., Best, Jan, Müller, Christian, Keitel, Verena, Venerito, Marino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737362/ https://www.ncbi.nlm.nih.gov/pubmed/36497447 http://dx.doi.org/10.3390/cancers14235966

Ejemplares similares

Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers
por: Himmelsbach, Vera, et al.
Publicado: (2022)

Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience
por: de Castro, Tiago, et al.
Publicado: (2022)

The CRAFITY score can identify patients with hepatocellular carcinoma showing poor response to treatment with atezolizumab and bevacizumab
por: Lieb, Sabine, et al.
Publicado: (2023)

Low 25-Hydroxyvitamin D Levels Are Associated with Infections and Mortality in Patients with Cirrhosis
por: Finkelmeier, Fabian, et al.
Publicado: (2015)

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2022)

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2023)

Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma—a European multicenter cohort
por: Pomej, K., et al.
Publicado: (2023)

Association of Common Polymorphisms in the Interleukin-1 Beta Gene with Hepatocellular Carcinoma in Caucasian Patients with Chronic Hepatitis B
por: Fischer, Janett, et al.
Publicado: (2022)

The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß‐catenin signaling
por: Krug, Sebastian, et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2022)

Secondary sclerosing cholangitis following COVID-19 disease: a multicenter retrospective study
por: Hunyady, Peter, et al.
Publicado: (2022)

Colonization with multidrug-resistant organisms impairs survival in patients with hepatocellular carcinoma
por: Himmelsbach, Vera, et al.
Publicado: (2021)

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
por: Wu, Yue Linda, et al.
Publicado: (2022)

Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review
por: Özdirik, Burcin, et al.
Publicado: (2021)

Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab
por: Jeschke, Matthias, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study
por: D’Alessio, Antonio, et al.
Publicado: (2022)

Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Evaluation of Ultrasound-based Surveillance for Hepatocellular Carcinoma in Patients at Risk: Results From a German Multicenter Retrospective Cohort Study
por: Gillessen, Johannes, et al.
Publicado: (2023)

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study
por: Joerg, Vincent, et al.
Publicado: (2023)

Hepatocellular carcinoma with gastric adenocarcinoma treated with atezolizumab and bevacizumab
por: Suga, Takayoshi, et al.
Publicado: (2023)

Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma
por: Brackenier, Cedric, et al.
Publicado: (2023)

Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma
por: Satake, Tomoyuki, et al.
Publicado: (2023)

Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma
por: Han, Ji Won, et al.
Publicado: (2023)

Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
por: AL Zahrani, Ali, et al.
Publicado: (2021)

Atezolizumab/bevacizumab: Severe encephalitis and immune-mediated polyradiculoneuropathy: case report
Publicado: (2021)

Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
por: Yano, Shigeki, et al.
Publicado: (2021)

A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
por: Watanabe, Yukinobu, et al.
Publicado: (2021)

Atezolizumab plus bevacizumab for patients with Child-Pugh-B in hepatocellular carcinoma
por: Itoh, Shinji, et al.
Publicado: (2022)

Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma
por: Yano, Yoshihiko, et al.
Publicado: (2023)

Duodenal Variceal Rupture during Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma
por: Tsuruoka, Mio, et al.
Publicado: (2022)

Serum Autotaxin Is a Parameter for the Severity of Liver Cirrhosis and Overall Survival in Patients with Liver Cirrhosis – A Prospective Cohort Study
por: Pleli, Thomas, et al.
Publicado: (2014)

Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer
por: Friedman, Claire F, et al.
Publicado: (2020)

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination
por: Tella, Sri Harsha, et al.
Publicado: (2022)

Atezolizumab and bevacizumab: the revolutionary duo as a game changer in advanced hepatocellular carcinoma
por: Zhang, D.X.
Publicado: (2020)

A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
por: Saito, Naoto, et al.
Publicado: (2022)

Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab
por: Nouso, Kazuhiro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rme2ok64iu394cb9tt08b2eak9